Health TrialsbyHealthPanel

The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health

ConditionsCardiovascular DiseasesAdiposityCardiometabolic Syndrome
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age45-70
SponsorUniversity of California, Davis

About this trial

Recently a dietary recommendation of 400 - 600 mg/ day has been proposed for the reduced risk of developing cardiovascular disease. Dietary flavanols can be obtained from the intake of foods such as tea, cocoa, wine, berries and apples. Incorporating Chardonnay Marc (the skins and seeds of Chardonnay grapes) into the diet can be an additional source of dietary flavanols. Like other flavanol-rich foods, Chardonnay Marc provides fiber and polysaccharides that may benefit gut health. This study seeks pilot data on the impact of the daily incorporation of Chardonnay Marc powder into the diet on markers of gut and cardiometabolic health.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Postmenopausal female, with a cessation of menses for at least 2 years

45-70 years of age

BMI 25- 49.9 kg/m2

Fasting triglycerides > 120 mg/dL

Disqualifiers

Self-reported use of daily anticoagulation agents including aspirin, NSAIDs

Prescription medications and supplements, except for a 6 month stable dose of thyroid medications

Vegan, Vegetarians, food faddists or those consuming a non-traditional diet

Fruit consumption ≥ 3 cups/day

Trial design

Design model

Sequential

Treatments tested in this trial

  • Chardonnay Marc

    Other intervention

    Food product made from Chardonnay wine grapes

Treatment groups

5 Participants
are divided into 2 treatment groups
Group A: Chardonnay Marc Intake Level 1Experimental treatment 1 intervention
Group B: Chardonnay Marc Intake Level 2Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Microvascular function

Microvascular function measured by peripheral arterial tonometry

Time frame
12 weeks

Secondary outcomes

1

Plasma Cholesterol

Circulating levels of plasma lipids

Time frame
12 weeks
2

Cytokines

Pro-inflammatory Th17 cytokines

Time frame
12 weeks
3

short chain fatty acids

Plasma and fecal levels of short chain fatty acids

Time frame
12 weeks
4

plasma bile acids

Circulating levels of primary and secondary bile acids

Time frame
12 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of California, Davis

Lead sponsor

Source ClinicalTrials.gov
Apply now